Total Payments
$865,285
2023 Payments
$1,123
Companies
35
Transactions
1,404
Medicare Patients
1,112
Medicare Billing
$671,184
Payment Breakdown by Category
Other$600,636 (69.4%)
Consulting$148,762 (17.2%)
Travel$64,263 (7.4%)
Food & Beverage$40,028 (4.6%)
Research$11,029 (1.3%)
Education$567.65 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $568,498 | 311 | 65.7% |
| Consulting Fee | $148,762 | 53 | 17.2% |
| Travel and Lodging | $64,263 | 225 | 7.4% |
| Food and Beverage | $40,028 | 783 | 4.6% |
| Honoraria | $29,551 | 15 | 3.4% |
| Unspecified | $11,029 | 7 | 1.3% |
| Grant | $2,588 | 3 | 0.3% |
| Education | $567.65 | 7 | 0.1% |
Payments by Type
General
$854,257
1,397 transactions
Research
$11,029
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $189,874 | 307 | $0 (2022) |
| Amgen Inc. | $136,304 | 164 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $122,441 | 159 | $0 (2022) |
| Lilly USA, LLC | $108,895 | 211 | $0 (2022) |
| AbbVie Inc. | $84,785 | 157 | $0 (2023) |
| Lundbeck LLC | $39,699 | 52 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $29,309 | 42 | $0 (2021) |
| IMPEL PHARMACEUTICALS INC. | $26,257 | 15 | $0 (2022) |
| Promius Pharma LLC | $21,011 | 31 | $0 (2019) |
| Supernus Pharmaceuticals, Inc. | $18,107 | 53 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,123 | 4 | PFIZER INC. ($940.00) |
| 2022 | $79,279 | 124 | IMPEL PHARMACEUTICALS INC. ($26,257) |
| 2021 | $213,758 | 313 | AbbVie Inc. ($60,744) |
| 2020 | $134,905 | 230 | Allergan, Inc. ($62,646) |
| 2019 | $177,628 | 306 | Amgen Inc. ($59,499) |
| 2018 | $168,802 | 254 | Amgen Inc. ($41,529) |
| 2017 | $89,792 | 173 | Allergan Inc. ($21,891) |
All Payment Transactions
1,404 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/17/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $106.35 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: RIMEGEPANT CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 03/08/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.92 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $69.42 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $46.08 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2022 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $78.35 | General |
| Category: PRIMARY CARE | ||||||
| 11/10/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Consulting Fee | In-kind items and services | $750.00 | General |
| Category: Migraine | ||||||
| 10/13/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Consulting Fee | Cash or cash equivalent | $8,752.00 | General |
| Category: Migraine | ||||||
| 10/13/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Consulting Fee | In-kind items and services | $1,500.00 | General |
| Category: Migraine | ||||||
| 10/13/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Consulting Fee | In-kind items and services | $1,500.00 | General |
| Category: Migraine | ||||||
| 10/13/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Food and Beverage | In-kind items and services | $68.75 | General |
| Category: Migraine | ||||||
| 10/13/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Travel and Lodging | In-kind items and services | $18.76 | General |
| Category: Migraine | ||||||
| 10/01/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Food and Beverage | In-kind items and services | $188.15 | General |
| Category: Migraine | ||||||
| 09/30/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Travel and Lodging | In-kind items and services | $749.20 | General |
| Category: Migraine | ||||||
| 09/30/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Food and Beverage | In-kind items and services | $146.42 | General |
| Category: Migraine | ||||||
| 09/08/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: PRIMARY CARE | ||||||
| 08/11/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Migraine | ||||||
| 07/29/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: PRIMARY CARE | ||||||
| 07/27/2022 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $562.50 | General |
| Category: NEUROSCIENCE | ||||||
| 07/27/2022 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $562.50 | General |
| Category: NEUROSCIENCE | ||||||
| 07/15/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 07/06/2022 | IMPEL PHARMACEUTICALS INC. | Trudhesa (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Migraine | ||||||
| 06/30/2022 | ABBVIE INC. | BOTOX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $562.50 | General |
| Category: NEUROSCIENCE | ||||||
| 06/28/2022 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $4,878 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,750 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $1,149 | 2 |
| RIMEGEPANT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $254.67 | 1 |
| RANDOMIZED CONTROLLED TRIAL OF LASMIDITAN OVER FOUR MIGRAINE ATTACKS | Eli Lilly and Company | $57.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 4 | 131 | 6,900 | $175,620 | $41,267 |
| 2021 | 16 | 573 | 55,320 | $1.5M | $372,399 |
| 2020 | 8 | 408 | 41,065 | $1.0M | $257,518 |
Total Patients
1,112
Total Services
103,285
Medicare Billing
$671,184
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 34 | 6,800 | $136,000 | $32,640 | 24.0% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 36 | 36 | $21,060 | $5,123 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 47 | 48 | $12,480 | $2,356 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 16 | $6,080 | $1,148 | 18.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 88 | 49,686 | $993,700 | $235,216 | 23.7% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2021 | 16 | 4,600 | $230,000 | $57,181 | 24.9% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 85 | 245 | $143,325 | $39,000 | 27.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 90 | 127 | $48,260 | $15,226 | 31.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 107 | 136 | $35,360 | $9,970 | 28.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 30 | 30 | $21,900 | $6,070 | 27.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 27 | 59 | $15,635 | $3,977 | 25.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $12,760 | $3,564 | 27.9% |
| 96374 | Injection of drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 15 | 21 | $2,940 | $848.45 | 28.9% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 14 | 19 | $2,185 | $605.31 | 27.7% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 15 | 31 | $1,860 | $514.64 | 27.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 11 | 12 | $720.00 | $151.92 | 21.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 13 | 246 | $1,230 | $30.30 | 2.5% |
| J3475 | Injection, magnesium sulfate, per 500 mg | Office | 2021 | 14 | 29 | $145.00 | $16.47 | 11.4% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2021 | 15 | 42 | $210.00 | $16.43 | 7.8% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2021 | 11 | 15 | $75.00 | $10.62 | 14.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 78 | 40,503 | $810,040 | $195,749 | 24.2% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 75 | 207 | $121,095 | $32,013 | 26.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 77 | 121 | $45,980 | $11,823 | 25.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 111 | 152 | $39,520 | $9,573 | 24.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 31 | 31 | $22,630 | $5,854 | 25.9% |
About Dr. Ira Turner, M.D
Dr. Ira Turner, M.D is a Neurology healthcare provider based in Plainview, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1306822929.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ira Turner, M.D has received a total of $865,285 in payments from pharmaceutical and medical device companies, with $1,123 received in 2023. These payments were reported across 1,404 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($568,498).
As a Medicare-enrolled provider, Turner has provided services to 1,112 Medicare beneficiaries, totaling 103,285 services with total Medicare billing of $671,184. Data is available for 3 years (2020–2022), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Plainview, NY
- Active Since 12/15/2005
- Last Updated 07/09/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1306822929
Products in Payments
- UBRELVY (Drug) $121,904
- BOTOX (Biological) $120,575
- Aimovig (Biological) $104,903
- AJOVY (Drug) $61,108
- EMGALITY (Drug) $45,764
- NURTEC ODT (Drug) $43,965
- VYEPTI (Biological) $39,552
- AJOVY (Biological) $39,511
- Trudhesa (Drug) $26,257
- Cambia (Drug) $25,805
- BOTOX (Drug) $24,893
- TROKENDI XR (Drug) $18,107
- REYVOW (Drug) $16,433
- Zembrace (Drug) $16,053
- TEV-48125 (Biological) $13,458
- TREXIMET (Drug) $8,701
- ONZETRA Xsail (Drug) $6,408
- AIMOVIG (Biological) $6,274
- ZEMBRACE SYMTOUCH (Drug) $4,868
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $4,087
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Plainview
Dr. Stephen Newman, M.d, M.D
Neurology — Payments: $1.2M
Neurology $1.2M
Dr. John Kelemen, M.d, M.D
Neurology — Payments: $168,048
Neurology $168,048
Jennifer Ahmed
Neurology — Payments: $27,427
Neurology $27,427
Dr. Erik Entin, M.d, M.D
Neurology — Payments: $4,988
Neurology $4,988
Dr. Vandana Soni, M.d, M.D
Neurology — Payments: $2,106
Neurology $2,106
Dr. Michael Gruttadauria, Dc, Dacan, DC, DACAN
Neurology — Payments: $10.79
Neurology $10.79